INSMED Inc — Director's Dealing 2025

Jan 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2025-01-07

Reporting Person: Flammer Martina M.D. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-07	Common Stock	S	3344	$65.91	Disposed	102766	Direct
2025-01-08	Common Stock	S	1702	$66.16	Disposed	101064	Direct
2025-01-08	Common Stock	A	6657	—	Acquired	107721	Direct
2025-01-10	Common Stock	S	1371	$63.73	Disposed	106350	Direct
2025-01-10	Common Stock	S	4801	$63.62	Disposed	101549	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-08	Stock Option (right to buy)	$65.72	A	31930	Acquired	2035-01-08	Common Stock (31930)	Direct

Footnotes

F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

F2: This is the weighted average sales price representing 3,344 shares sold at prices ranging from $65.57 to $65.99 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F3: Due to a clerical error related to the reporting of shares previously withheld by the Company to satisfy tax obligations upon the vesting of RSUs, this number was previously overstated by 24 shares. This value reflects the adjustment, decreasing the amount beneficially owned by 24 shares.

F4: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F5: Each RSU was granted on January 8, 2025 for no consideration.

F6: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.